Member Info for djwall1s

That would be my hope. It's not unusual for many companies to have investor hubs and ANA is a little later in the day with it but it's a great central homebase for investors to access everything they need.

RNS - Ananda Launches New Interactive Investor Hub

Today 07:00

RNS Number : 6859W

Ananda Developments PLC

14 December 2023

Reach - Non-Regulatory

Ananda Developments plc

("Ananda" or the "Company")

Ananda Developments Launches New Interactive Investor Hub, investors.anandadevelopments.com to provide stakeholders with a more proactive method of communication and enquiry support

Ananda Developments Plc ('Ananda') a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions is pleased to announce the launch of Ananda's Interactive Investor Hub. For both existing and prospective stakeholders it brings all Ananda's content into a single integrated platform to better inform and engage with investors and stakeholders, including:

regulatory announcements

annual and interim reports

corporate presentations

educational material

Interviews with the company's directors

corporate research on Ananda Developments

Investor Hub also provides an interactive online experience allowing the Company's stakeholders to comment on and ask the Ananda team questions via a portal which will be monitored and responded to promptly. Company RNSs will also still be released via the current regulated services.

To sign up for the Ananda Investor Hub:

1. Visit investors.anandadevelopments.com

2. Follow the prompts to sign up for an investor hub account

3. Complete your account profile

Ananda's CEO, Melissa Sturgess commented: "We have always encouraged our stakeholders to engage with us. We see Investor Hub as an effective platform upon which to further enable our stakeholders including shareholders, potential shareholders and interested parties to interact with Ananda. Investor Hub will also allow us to share more video material, information and insights about our activities and plans. We encourage our shareholders, potential shareholders and wider stakeholders to trial Investor Hub and provide feedback."

Mop up.

Yes, it was positive. He answered several questions from our shareholders group, which is on its way towards 80 members, answered ither questions and stayed back to mo up for about half an hour after the session ended.

To sum up I'd say that he seems in a positive frame of mind but critically March is when the Deccan shares that Tally has are unlocked. That should help us get over the line, in theory. The next 4 months will be crucial.

Matabrown, seems you fell through a crack there, buddy. I have resent you a join link via Telegram. Just click on it and I'll add you in when you appear again. Cheers.

...buying here and intend to be in for 5 years+, building a pot up slowly month by month. I've read all the comments, those in favour and those not, and I think I will enjoy this one. It looks like a solid longterm investment. I thank Rzez for the helpful advice also.

Gotcha, cheers.

I should just mention again, there is nobody awaiting to join with numbers in their name. I have neither a 6 nor a 7, or reversed, in any shape or form. Cheers.

Thank you. Added.

See message to you there. Cheers.

Au, I have nobody with those initials waiting. Are you in the correct Tally group?

Hi saf, it is there. It should come up under Tally, Lionsgold, or a combination of the two.

Pans out.

I also really enjoyed the presentation. I felt that Melissa padded things out, tackled questions head on and answered them evenly without sofsoaping or embellishing. Good things are on the horizon if this pays out, and frameworks are being fitted. The growing is only paused, not killed off. Patience for the sp, it is what it is at present. And the future is not just with Scottish NHS but UK wide, with Scotland being a really good base. They hope to be global some day.

All in all, a most enjoyable and informative listen imo! Thank you.

I'm not exactly sure what Gary is even doing here any more? Again, if you hate it so much, leave. People are hardly going to stop posting stuff that relates to the company on the company's own forum. And LSE is hardly going to allow a premium-registered 'Melissa Sturgess' to troll a forum that the real Melissa Sturgess can easily monitor and complain about if she feels her identity has been lifted and some rando is speaking on her behalf. Do you actually understand how the world works?

It's as if you're shocked that people have the temerity to post. You bring yourself here and then have tantrums with people, like you did in the Telegram group. If you're compelled to be like this all the time then that's on you, not other people.

I'm open to any company criticism as well as praise where due. I've also seen boiler roomers and trolls make various forums all about them, work in tag teams or packs, and try and distract and deviate from conversation about the company. This time you are the one blocked and so is that cuckoo fella. You're both a royal time-wasting miss imo. I won't be including either of you. Or just the one of you, in future mentions. And I suggest others do the same.

Lord, imagine being this bitter and toxic about a company you choose to sniff around. Classic boiler room baiting. I thought it had died out with the parrots and barmen but apparently not.

Cheers.:)

Looks that way. :)

Also getting, and keeping, away from this soul-destroying sp level will also be a welcome step up.

ANANDA DEVELOPMENTS PLC

Investor Presentation

14th Nov 2023 at 9:00am GMT

The RCT, funded by a £1.25m non-dilutive grant, is being led by Professor Marie Fallon a leading researcher at UofE. Professor Fallon is the St Columba's Hospice Chair of Palliative Medicine and Honorary Consultant in Palliative Care and has 256 publications and over 10,000 citations to her name. The trial will be a double-blind crossover trial, located at Western General Hospital with a 92?patient recruitment plan.

CIPN is a common and debilitating side effect of chemotherapy with approximately 160,000 new cases per year in the UK, with a prevalence 3 months after a chemotherapy treatment of 60%. There are no preventative treatments for CIPN, and symptomatic management is commonly ineffective. The CIPN global market was valued at US$1bn in 2021 and is estimated to reach US$1.5bn in 2030 and given most treatments are ineffective, the Directors believe that this figure does not accurately reflect the true market size.

Rationale for the research:

1. CIPN is a common condition and distressing to patients with no preventative options and no effective treatment to date.

2. Self-medication with cannabis is common, but clinical use lacks empirical evidence on efficacy and safety.

3. This research addresses calls from NICE and IASP (International Association for the Study of Pain) for cannabis-based medicine research. Following their reviews of the evidence, this research aligns with their recommendations for the choice of CBD and methodology (IASP) in CBD trials.

4. In addition, the trials are following guidelines for assessments in CIPN trials and have added mechanistic assessments.

5. There is strong preclinical evidence to match CIPN and CBD.

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:

· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=

· LinkedIn: https://www.linkedin.com/company/anadevelopments/

· Twitter: https://twitter.com/anandaplc?s=21&t=9yeIC_xYCfzgDn7j26sfuA

· Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

-Ends-